DAPAVO, P.; MEGNA, M.; TALAMONTI, M. Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis. Dermatology Reports, [S. l.], 2024. DOI: 10.4081/dr.2024.9999. Disponível em: https://www.pagepress.org/journals/dr/article/view/9999. Acesso em: 25 aug. 2024.